Research programme: infectious disease therapeutics - Cue Biopharma
Alternative Names: Cue 200 series - Cue Biopharma; CUE-201; synTacs™Latest Information Update: 15 Apr 2023
At a glance
- Originator Cue Biopharma
- Developer Albert Einstein College of Medicine; Cue Biopharma
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action CD137 antigen modulators; CD28 antigen modulators; CD80 antigen modulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cytomegalovirus infections; HIV-1 infections; Infections
Most Recent Events
- 21 Mar 2023 Research programme: infectious disease therapeutics - Cue Biopharma is available for licensing as of 31 Dec 2022. https://www.cuebiopharma.com/partnering/
- 19 Oct 2021 Preclinical trials in Cytomegalovirus infections in USA (Parenteral)
- 19 Oct 2021 Preclinical trials in HIV-1 infections in USA (Parenteral)